Page 119 - Read Online

Nociti. Neuroimmunol Neuroinflammation 2020;7:291-9 I http://dx.doi.org/10.20517/2347-8659.2020.25 Page 297

However, the challenge for neuroprotection in MS is greater than in other brain disease, because MS
requires the association of both neuroprotective and immunomodulation therapies. Any exclusive
inflammatory suppression is likely required to abolish both destructive and protective components and any
neuroprotective treatment cannot work without a powerful anti-inflammatory therapy.

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Naegele M, Martin R. The good and the bad of neuroinflammation in multiple sclerosis. Handb Clin Neurol 2014;122:59-87.
2. Gold R, Montalban X. Multiple sclerosis: more pieces of the immunological puzzle. Lancet Neurol 2012;11:9-10.
3. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the
McDonald criteria. Ann Neurol 2011;69:292-302.
4. Stys PK, Tsutsui S. Recent advances in understanding multiple sclerosis. F1000Res 2019;8:2100.
5. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet 2018;391:1622-36.
6. Machado-Santos J, Saji E, Tröscher AR, Paunovic M, Liblau R, et al. The compartmentalized inflammatory response in the multiple
sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain 2018;141:2066-82.
7. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, et al. Neuroprotection by encephalomyelitis: rescue of mechanically
injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283-91.
8. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, et al. Autoimmune T cells protect neurons from secondary degeneration after
central nervous system axotomy. Nat Med 1999;5:49-55.
9. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther 2009;121:147-59.
10. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the
therapy of multiple sclerosis. Neurol Sci 2006;27 Suppl 1:S1-7.
11. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune
systems: implications for neurological diseases. Ann Neurol 2003;53:292-304.
12. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, et al. Activated human T cells, B cells, and monocytes produce
brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med
1999;189:865-70.
13. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, et al. BDNF and gp145trkB in multiple sclerosis brain lesions:
neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75-85.
14. De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, et al. Neuroinflammation and neuroprotection: an update on (future)
neurotrophin-related strategies in multiple sclerosis treatment. Curr Med Chem 2011;18:1775-84.
15. Li R, Patterson K, Bar-Or A. Reassessing the contributions of B cells in multiple sclerosis. Nat Rev Immunol 2018;19:696-707.